Peculiarities of BRCA1/2 testing in patients with advanced HER2-negative breast cancer in the Russian Federation (results of a survey of Russian oncologists)
https://doi.org/10.18027/2224-5057-2021-11-2-38-44
Abstract
Hereditary BRCA1 / 2 mutations affect the strategy of surgical treatment in early cancer and systemic treatment in advanced HER2-negative breast cancer. The article presents the results of a survey of Russian oncologists on various aspects of genetic testing for hereditary BRCA1 / 2 mutations in real-world clinical practice. Indications for testing, testing methods, and funding sources were discussed.
About the Authors
M. A. Frolova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Mona A. Frolova - MD, PhD, DSc, Leading Research Associate, Chemotherapy Department N1, N.N. Blokhin National Medical Research Center of Oncology.
Moscow.
Competing Interests:
No
M. B. Stenina
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Marina B. Stenina - MD, PhD, DSc, Leading Research Associate, Chemotherapy Department N1, N.N. Blokhin National Medical Research Center of Oncology.
Moscow.
Competing Interests:
No
References
1. A. Antoniou, P.D.P. Pharoah, S.Narod, H.A.Risch, J.E. Eyfjord, J.L. Hopper, et al. Average risks of breast and ovarian cancer associated with BRCAl or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet, 72 (2003), pp. 1117‑1130.
2. A.H. Аюбченко, Е.И. Батенева, И.К. Воротников, С.М. Портной, О.В. Крохина, В.А. Соболевский, Л.Г. Жукова, В.А. Хайленко, С.А. Тюляндин. Наследственный рак молочной железы: генетическая и клиническая гетерогенность, молекулярная диагностика, хирургическая профилактика в группах риска. Успехи молекулярной онкологии, 20l4 г.; №2, с. 16-25.
3. K.B. Kuchenbaecker, J.L. Hopper, D.R. Barnes, K.-A. Phillips, T.M. Mooij, M.-J. Roos-Blom, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCAl and BRCA2 mutation carriers. JAMA, 3l7 (2017), pp. 2402-2416.
4. 4 Mark Robson, Seock-Ah Im, Elzbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong, Wenting Wu, Carsten Goessl, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 20l7; 377:523-533. DOI: 10.1056/NEJMoa1706450.
5. Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Goncalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin, Henri Roche, Young-Hyuck Im, Ruben G W Quek, Denka Markova, Iulia C Tudor, Alison L Hannah, Wolfgang Eiermann, Joanne L Blum. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med; 2018 Aug 23;379(8):753-763. DOI: 10.1056/NEJMoa1802905.
6. Стенина М.Б., Жукова Л. Г., Королева И. А., Пароконная А. А., Семиглазова Т. Ю., Тюляндин С.А., Фролова М.А. Инвазивный рак молочной железы. Злокачественные опухоли 2020; том 10 №3s2, с. 150-187. DOI: 10.18027/2224-5057-2020-10-3s2-09.
7. Инструкция по медицинскому применению лекарственного препарата Талценна (РУ ЛП-006116 от 28.02.2020).
8. Инструкция по медицинскому применению лекарственного препарата Линпарза (РУ ЛП-005941 от 26.11.2019).
9. Рекомендации Минздрава РФ «Рак молочной железы», 2019 г.
10. Lux MP, Niyazov A, Lewis K et al. Real-world (RW) Multi-country Study of BRCA1/2 Testing in Adult Patients (pts) With HER2- Advanced Breast Cancer (ABC). Poster 314P. ESMO 2020.
11. Mahtani P, Niyazov A, Lewis K et al. Real-world (RW) Multi-country Study of BRCA1/2 Mutation (BRCA1/2mut) Testing Trends Among Adult Patients (pts) With HER2- Advanced Breast Cancer (ABC). Poster 312P. ESMO 2020.
12. Michael P. Luxa, Thomas Decker, Eva Diana Runkel, Alexander Niyazov, Ruben G.W. Quek, Norbert Marschner, Nadia Harbeck. Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany. Breast Care DOI: 10.1159/000513596.
13. Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019 Jul; 11: 543-61.
14. Постановление Правительства РФ от 28.12.2020 N 2299 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2021 год и на плановый период 2022 и 2023 годов».
15. Постановление Правительства РФ от 7 декабря 2019 г. N 1610 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2020 год и на плановый период 2021 и 2022 годов».
Review
For citations:
Frolova M.A., Stenina M.B. Peculiarities of BRCA1/2 testing in patients with advanced HER2-negative breast cancer in the Russian Federation (results of a survey of Russian oncologists). Malignant tumours. 2021;11(2):38-44. (In Russ.) https://doi.org/10.18027/2224-5057-2021-11-2-38-44
Views:
468
Email this article 